Review of recently used techniques and materials to improve the efficiency of orally administered proteins/peptides
Tóm tắt
The main objective of present review is to explore and evaluate the effectiveness of recently developed methods to improve the bioavailability of orally administered biopharmaceutical drugs.
A systematic search of sciencedirect, tandfonline and Google Scholar databases based on various sets of keywords was performed. All results were evaluated based on their abstracts, and irrelevant studies were neglected during further evaluation.
At present, biopharmaceuticals are used as injectable therapies as they are not absorbed adequately from the different routes of drug administration, particularly the oral one. Their insufficient absorption is attributed to their high molecular weight, degradation by proteolytic enzymes, high hydrophilicity and rigidity of the absorptive tissues. From industrial aspect incorporation of enzyme inhibitors (EIs) and permeation enhancers (PEs) and mucoadhesive polymers into conventional dosage forms may be the easiest way of formulation of orally administered macromolecular drugs, but the effectiveness of protection and absorption enhancement here is the most questionable. Conjugation may be problematic from regulatory aspect. Encapsulation into lipid-based vesicles sufficiently protects the incorporated macromolecule and improves intestinal uptake but have considerable stability issues. In contrast, polymeric nanocarriers may provide good stability but provides lower internalization efficacy in comparison with the lipid-based carriers.
It can be concluded that the combination of the advantages of mucoadhesive polymeric and lid-based carriers in hybrid lipid/polymer nanoparticles may result in improved absorption and might represent a potential means for the oral administration of therapeutic proteins in the near future.
Từ khóa
Tài liệu tham khảo
Keservani RK, Sharma AK, Jarouliya U. Protein and peptide in drug targeting and its therapeutic approach. Ars Pharmaceutica (Internet). 2015;56:165–77.
Mansour SC, Pena OM, Hancock REW. Host defense peptides: front-line immunomodulators. Trends Immunol. 2014;35:443–50.
Kwon K-C, Daniell H. Oral delivery of protein drugs bioencapsulated in plant cells. Mol Ther. 2016;24:1342–50.
Batista P, Castro PM, Madureira AR, Sarmento B, Pintado M. Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides. Peptides. 2018;101:112–23.
Semalty A, Semalty M, Singh R, Saraf S, Saraf S. Properties and formulation of oral drug delivery systems of protein and peptides. Indian J Pharm Sci. 2007;69:741.
Muheem A, Shakeel F, Jahangir MA, Anwar M, Mallick N, Jain GK, Warsi MH, Ahmad FJ. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm J. 2016;24:413–28.
Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13:655–72.
Agrawal GR, Wakte P, Shelke S. Formulation, physicochemical characterization and in vitro evaluation of human insulin-loaded microspheres as potential oral carrier. Prog Biomater. 2017;6:125–36.
Toorisaka E, Watanabe K, Ono H, Hirata M, Kamiya N, Goto M. Intestinal patches with an immobilized solid-in-oil formulation for oral protein delivery. Acta Biomater. 2012;8:653–8.
Santalices I, Gonella A, Torres D, Alonso MJ. Advances on the formulation of proteins using nanotechnologies. J Drug Delivery Sci Technol. 2017;42:155–80.
Truong-Le V, Lovalenti PM, Abdul-Fattah AM. Stabilization challenges and formulation strategies associated with oral biologic drug delivery systems. Adv Drug Deliv Rev. 2015;93:95–108.
Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008;70:269.
Lundquist P, Artursson P. Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations and studies in human tissues. Adv Drug Deliv Rev. 2016;106:256–76.
Wong CY, Al-Salami H, Dass CR. Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. J Control Release. 2017;264:247–75.
Renukuntla J, Vadlapudi AD, Patel A, Boddu SHS, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 2013;447:75–93.
Solaro R, Chiellini F, Battisti A. Targeted delivery of protein drugs by nanocarriers. Materials. 2010;3:1928–80.
Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20:153–214.
Kompella UB, Lee VHL. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev. 2001;46:211–45.
Hetal T, Bindesh P, Sneha T. A review on oral Techniques for oral bioavailability. Int J Pharm Sci Rev Res. 2010;4:033. Available from: https://pdfs.semanticscholar.org/0dd6/cc180bdabeab5bc627dcbbff2567735f494f.pdf
Pawar VK, Meher JG, Singh Y, Chaurasia M, Surendar Reddy B, Chourasia MK. Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives. J Control Release. 2014;196:168–83.
Salama N, Eddington N, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev. 2006;58:15–28.
Bakhru SH, Furtado S, Morello AP, Mathiowitz E. Oral delivery of proteins by biodegradable nanoparticles. Adv Drug Deliv Rev. 2013;65:811–21.
DiMarco RL, Hunt DR, Dewi RE, Heilshorn SC. Improvement of paracellular transport in the Caco-2 drug screening model using protein-engineered substrates. Biomaterials. 2017;129:152–62.
Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124:3–20.
Lemmer HJ, Hamman JH. Paracellular drug absorption enhancement through tight junction modulation. Expert Opin Drug Deliv. 2013;10:103–14.
Shaikh. Permeability enhancement techniques for poorly permeable drugs: a review. J Appl Pharmaceut Sci. 2012;02(06):34–9. [cited 2018 Apr 21]; Available from: http://www.japsonline.com/abstract.php?article_id=543
Lechanteur A, das Neves J, Sarmento B. The role of mucus in cell-based models used to screen mucosal drug delivery. Adv Drug Delivery Rev. 2018;124:50–63.
Boegh M, Nielsen HM. Mucus as a barrier to drug delivery - understanding and mimicking the barrier properties. Basic Clin Pharmacol Toxicol. 2015;116:179–86.
Patel G, Misra A. Oral delivery of proteins and peptides. In: Misra A, editor. Challenges in delivery of therapeutic genomics and proteomics [Internet]. London: Elsevier; 2011. p. 481–529. [cited 2018 Apr 22] Available from: http://linkinghub.elsevier.com/retrieve/pii/B9780123849649000104.
Ismail R, Csóka I. Novel strategies in the oral delivery of antidiabetic peptide drugs – insulin, GLP 1 and its analogs. Eur J Pharm Biopharm. 2017;115:257–67.
Maher S, Mrsny RJ, Brayden DJ. Intestinal permeation enhancers for oral peptide delivery. Adv Drug Deliv Rev. 2016;106:277–319.
Ozer S, Kerimoglu O, Ugurlu T. Nanocarriers: novel approaches to oral delivery of insulin. Clin Experimental Health Sci. 2017;7:115–22.
Alexander A, Ajazuddin M, Swarna M, Sharma M, Tripathi D. Polymers and permeation enhancers: specialized components of mucoadhesives. Stamford J Pharmaceut Sci [Internet]. 2011;4(1):91–5. [cited 2018 Apr 22]; Available from: http://www.banglajol.info/index.php/SJPS/article/view/8878
McCartney F, Gleeson JP, Brayden DJ. Safety concerns over the use of intestinal permeation enhancers: a mini-review. Tissue Barriers. 2016;4:e1176822.
Whitehead K, Karr N, Mitragotri S. Safe and effective permeation enhancers for oral drug delivery. Pharm Res. 2008;25:1782–8.
Singh D, Sharma PK, Sara UVS. Enhancement of intestinal absorption of poorly absorbed drugs by using various permeation enhancers: an overview. World J Pharm Pharmaceut Sci. 2013;2(1):179–98.
Wong SM, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm. 2006;317:61–8.
Al-Ali AAA, Steffansen B, Holm R, Nielsen CU. Nonionic surfactants increase digoxin absorption in Caco-2 and MDCKII MDR1 cells: impact on P-glycoprotein inhibition, barrier function, and repeated cellular exposure. Int J Pharm. 2018;551:270–80.
Sangsen Y, Wiwattanawongsa K, Likhitwitayawuid K, Sritularak B, Graidist P, Wiwattanapatapee R. Influence of surfactants in self-microemulsifying formulations on enhancing oral bioavailability of oxyresveratrol: studies in Caco-2 cells and in vivo. Int J Pharm. 2016;498:294–303.
Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev. 2001;52:117–26.
van der Merwe SM, Verhoef JC, Verheijden JHM, Kotzé AF, Junginger HE. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm. 2004;58:225–35.
Sadeghi A, Dorkoosh F, Avadi M, Weinhold M, Bayat A, Delie F, Gurny R, Larijani B, Rafiee-Tehrani M, Junginger HE. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur J Pharm Biopharm. 2008;70:270–8.
Zhang Z, Gao F, Jiang S, Chen L, Liu Z, Yu H, Li Y. Bile salts enhance the intestinal absorption of lipophilic drug loaded lipid nanocarriers: mechanism and effect in rats. Int J Pharm. 2013;452:374–81.
Niu M, Tan Y, Guan P, Hovgaard L, Lu Y, Qi J, Lian R, Li X, Wu W. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int J Pharm. 2014;460:119–30.
Elmowafy M, Shalaby K, Badran MM, Ali HM, Abdel-Bakky MS, El-Bagory I. Fatty alcohol containing nanostructured lipid carrier (NLC) for progesterone oral delivery: in vitro and ex vivo studies. J Drug Delivery Sci Technol. 2018;45:230–9.
Gupta V, Hwang BH, Doshi N, Mitragotri S. A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine. J Control Release. 2013;172:541–9.
Hussain A, Arnold JJ, Khan MA, Ahsan F. Absorption enhancers in pulmonary protein delivery. J Control Release. 2004;94:15–24.
Sonaje K, Lin K-J, Tseng MT, Wey S-P, Su F-Y, Chuang E-Y, Hsu CW, Chen CT, Sung HW. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials. 2011;32:8712–21.
Fan B, Xing Y, Zheng Y, Sun C, Liang G. pH-responsive thiolated chitosan nanoparticles for oral low-molecular weight heparin delivery: in vitro and in vivo evaluation. Drug Delivery. 2016;23:238–47.
Nur M, Vasiljevic T. Can natural polymers assist in delivering insulin orally? Int J Biol Macromol. 2017;103:889–901.
Lin P-Y, Chuang E-Y, Chiu Y-H, Chen H-L, Lin K-J, Juang J-H, Chiang CH, Mi FL, Sung HW. Safety and efficacy of self-assembling bubble carriers stabilized with sodium dodecyl sulfate for oral delivery of therapeutic proteins. J Control Release. 2017;259:168–75.
Moghimipour E, Ameri A, Handali S. Absorption-enhancing effects of bile salts. Molecules. 2015;20:14451–73.
Nurunnabi M, Khatun Z, Revuri V, Nafiujjaman M, Cha S, Cho S, et al. Design and strategies for bile acid mediated therapy and imaging. RSC Adv. 2016;6:73986–4002.
Aguirre TAS, Teijeiro-Osorio D, Rosa M, Coulter IS, Alonso MJ, Brayden DJ. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv Drug Deliv Rev. 2016;106:223–41.
Park K, Kwon IC, Park K. Oral protein delivery: current status and future prospect. React Funct Polym. 2011;71:280–7.
Ansari MJ. Role of protease inhibitors in insulin therapy of diabetes: are these beneficial. Bull Environ Pharmacol Life Sci. 2015;4:1–8.
Jain AK, Jain SK, Chalasani KB. Non-invasive systemic delivery of proteins (s) and peptide (s). Pharmagene. 2013;1:73–84.
Agarwal V, Reddy IK, Khan MA. Polymethyacrylate based microparticulates of insulin for oral delivery: preparation and in vitro dissolution stability in the presence of enzyme inhibitors. Int J Pharm. 2001;225:31–9.
Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4:1443–67.
Choonara BF, Choonara YE, Kumar P, Bijukumar D, du Toit LC, Pillay V. A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv. 2014;32:1269–82.
Herrero EP, Alonso MJ, Csaba N. Polymer-based oral peptide nanomedicines. Ther Deliv. 2012;3:657–68.
Hassani LN, Lewis A, Richard J. Oral peptide delivery: technology landscape and current status. OnDrugDelivery. 2015;59:12–7.
Roy S, Pal K, Anis A, Pramanik K, Prabhakar B. Polymers in mucoadhesive drug-delivery systems: a brief note. Des Monomers Polym. 2009;12:483–95.
Saraswathi B, Balaji A, Umashankar MS. Polymers in mucoadhesive drug delivery system-latest updates. Int J Pharm Pharmaceut Sci. 2013;5:423–30.
Vijapur LS, Sreenivas SA, Patil SH, Vijapur PV, Patwari PK, Saraswathi. Thiolated chitosan: a novel mucoadhesive polymer: a review. Int Res J Pharam. 2012;3(4):51–7.
Carvalho FC, Bruschi ML, Evangelista RC, Gremião MPD. Mucoadhesive drug delivery systems. Braz J Pharmaceut Sci. 2010;46:1–17.
Boddupalli BM, Mohammed ZN, Nath RA, Banji D. Mucoadhesive drug delivery system: an overview. J Adv Pharm Technol Res. 2010;1:381.
Phanindra B, Moorthy BK, Muthukumaran M. Recent advances in mucoadhesive/bioadhesive drug delivery system: a review. Int J Pharma Med Biol Sci. 2013;2(1):68–84.
Khafagy E-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev. 2007;59:1521–46.
Banerjee A, Mitragotri S. Intestinal patch systems for oral drug delivery. Curr Opin Pharmacol. 2017;36:58–65.
Banerjee A, Lee J, Mitragotri S. Intestinal mucoadhesive devices for oral delivery of insulin. Bioeng Translational Med. 2016;1:338–46.
Swaminathan J, Ehrhardt C. Liposomal delivery of proteins and peptides. Expert Opin Drug Deliv. 2012;9:1489–503.
Palazzo C, Trapani G, Ponchel G, Trapani A, Vauthier C. Mucoadhesive properties of low molecular weight chitosan- or glycol chitosan- and corresponding thiomer-coated poly (isobutylcyanoacrylate) core-shell nanoparticles. Eur J Pharm Biopharm. 2017;117:315–23.
Fonte P, Araújo F, Reis S, Sarmento B. Oral insulin delivery: how far are we? J Diabetes Sci Technol. 2013;7:520–31.
Jiang W-Z, Cai Y, Li H-Y. Chitosan-based spray-dried mucoadhesive microspheres for sustained oromucosal drug delivery. Powder Technol. 2017;312:124–32.
Khan S, Parvez N, Sharma PK. Novel natural mucoadhesive polymers. 2015;4:374-388.
Sreenivas SA, Pai KV. Thiolated chitosans: novel polymers for mucoadhesive drug delivery–a review. Trop J Pharm Res. 2008;7:1077–88.
Bernkop-Schnürch A, Steininger S. Synthesis and characterisation of mucoadhesive thiolated polymers. Int J Pharm. 2000;194:239–47.
Laffleur F, Psenner J, Suchaoin W. Permeation enhancement via thiolation: in vitro and ex vivo evaluation of hyaluronic acid-cysteine ethyl ester. J Pharm Sci. 2015;104:2153–60.
Kumar R, Sinha VR. Thiomer: a potential carrier for therapeutic delivery. React Funct Polym. 2013;73:1156–66.
Mythri G, Kavitha K, Kumar MR, Singh S. Novel mucoadhesive polymers–a review. 2011;01(08):37-42
Mahmood A, Bonengel S, Laffleur F, Ijaz M, Leonaviciute G, Bernkop-Schnürch A. An in-vitro exploration of permeation enhancement by novel polysulfonate thiomers. Int J Pharm. 2015;496:304–13.
Abet V, Filace F, Recio J, Alvarez-Builla J, Burgos C. Prodrug approach: an overview of recent cases. Eur J Med Chem. 2017;127:810–27.
Jitendra PK, Bansal S, Banik A. Noninvasive routes of proteins and peptides drug delivery. Indian J Pharm Sci. 2011;73:367.
Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006;11:905–10.
Pérez Y, Urista C, Martínez J, Nava M, Rodríguez F. Functionalized polymers for enhance oral bioavailability of sensitive molecules. Polymers. 2016;8:214.
Grigoletto A, Maso K, Mero A, Rosato A, Schiavon O, Pasut G. Drug and protein delivery by polymer conjugation. J Drug Delivery Sci Technol. 2016;32:132–41.
Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001;22:405–17.
Goodwin D, Simerska P, Toth I. Peptides as therapeutics with enhanced bioactivity. Curr Med Chem. 2012;19:4451–61.
Ratnaparkhi MP, Chaudhari SP, Pandya VA. Peptides and proteins in pharmaceuticals. Int J Curr Pharm Res. 2011;3:1–9.
Castro PM, Fonte P, Sousa F, Madureira AR, Sarmento B, Pintado ME. Oral films as breakthrough tools for oral delivery of proteins/peptides. J Control Release. 2015;211:63–73.
Yin N, Brimble MA, Harris PWR, Wen J. Enhancing the oral bioavailability of peptide drugs by using chemical modification and other approaches. Med Chem. 2014;4:763–9.
Mahajan A, Rawat AS, Bhatt N, Chauhan MK. Structural modification of proteins and peptides. Indian J Pharm Educ Res. 2014;48:34–47.
Nadolski MJ, Linder ME. Protein lipidation: function and mechanism of palmitoylation. FEBS J. 2007;274:5202–10.
Kristensen M, Nielsen HM. Cell-penetrating peptides as carriers for oral delivery of biopharmaceuticals. Basic Clin Pharmacol Toxicol. 2016;118:99–106.
Rehmani S, Dixon JE. Oral delivery of anti-diabetes therapeutics using cell penetrating and transcytosing peptide strategies. Peptides. 2018;100:24–35.
Buckley ST, Hubálek F, Rahbek UL. Chemically modified peptides and proteins - critical considerations for oral delivery. Tissue Barriers. 2016;4:e1156805.
Lee E, Lee J, Jon S. A novel approach to oral delivery of insulin by conjugating with low molecular weight chitosan. Bioconjug Chem. 2010;21:1720–3.
Sheng J, He H, Han L, Qin J, Chen S, Ru G, Li R, Yang P, Wang J, Yang VC. Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates. J Control Release. 2016;233:181–90.
Niu Z, Conejos-Sánchez I, Griffin BT, O’Driscoll CM, Alonso MJ. Lipid-based nanocarriers for oral peptide delivery. Adv Drug Deliv Rev. 2016;106:337–54.
Mu H, Holm R, Müllertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int J Pharm. 2013;453:215–24.
Rawat M, Singh D, Saraf S, Saraf S. Lipid carriers: a versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi. 2008;128:269–80.
Laouini A, Jaafar-Maalej C, Limayem-Blouza I, Sfar S, Charcosset C, Fessi H. Preparation, characterization and applications of liposomes: state of the art. J Colloid Sci Biotechnol. 2012;1:147–68.
Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery–liposomes versus lipid nanoparticles. Int J Nanomedicine. 2007;2:595.
Kalepu S, Sunilkumar KT, Betha S, Mohanvarma M. Liposomal drug delivery system—a comprehensive review. Int J Drug Dev Res. 2013;5:62–75.
Vela Ramirez JE, Sharpe LA, Peppas NA. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev. 2017;114:116–31.
Ahn H, Park J-H. Liposomal delivery systems for intestinal lymphatic drug transport. Biomaterials Res. 2016;20:36. [cited 2018 Apr 23];20. Available from: http://biomaterialsres.biomedcentral.com/articles/10.1186/s40824-016-0083-1
Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci. 2010;99:2557–75.
Yadav A, Murthy MS, Shete AS, Sakhare S. Stability aspects of liposomes. Indian J Pharmaceut Educ Res. 2011;45:402–13.
Xu X, Costa A, Burgess DJ. Protein encapsulation in unilamellar liposomes: high encapsulation efficiency and a novel technique to assess lipid-protein interaction. Pharm Res. 2012;29:1919–31.
Chin J, Foyez Mahmud KA, Kim SE, Park K, Byun Y. Insight of current technologies for oral delivery of proteins and peptides. Drug Discov Today Technol. 2012;9:e105–12.
Sipai ABM, Vandana Y, Mamatha Y, Prasanth VV. Liposomes: an overview. J Pharm Sci Innov. 2012;1:13–21.
Lila ASA, Ishida T. Liposomal delivery systems: design optimization and current applications. Biol Pharm Bull. 2017;40:1–10.
Sarmento B, Martins S, Ferreira D, Souto EB. Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomedicine. 2007;2:743.
Ansari MJ, MdK A, Jamil S, Al-Shdefat R, Ali BE, Ahmad MM, et al. Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. Drug Delivery. 2015;23:1972–9.
Kim H, Kim Y, Lee J. Liposomal formulations for enhanced lymphatic drug delivery. Asian J Pharm Sci. 2013;8:96–103.
Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev. 2011;63:901–8.
Jawahar N, Meyyanathan SN, Reddy G, Sood S. Solid lipid nanoparticles for oral delivery of poorly soluble drugs. J Pharm Sci Res. 2012;4:1848.
Ganesan P, Narayanasamy D. Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain Chem Pharm. 2017;6:37–56.
Yassin AEB, Albekairy A, Alkatheri A, Sharma RK. Anticancer-loaded solid lipid nanoparticles: high potential advancement in chemotherapy. Dig J Nanomater Biostruct. 2013;8:905–16.
Ma T, Wang L, Wang D, Ma G, Wang S. PLGA–lipid liposphere as a promising platform for oral delivery of proteins. Colloids Surf B: Biointerfaces. 2014;117:512–9.
Tezgel Ö, Szarpak-Jankowska A, Arnould A, Auzély-Velty R, Texier I. Chitosan-lipid nanoparticles (CS-LNPs): application to siRNA delivery. J Colloid Interface Sci. 2018;510:45–56.
des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116:1–27.
De Kruif JK, Varum F, Bravo R, Kuentz M. A systematic study on manufacturing of prilled microgels into lipids for oral protein delivery. J Pharm Sci. 2015;104:3351–65.
Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev. 2013;65:822–32.
Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64:557–70.
Tiyaboonchai W. Chitosan nanoparticles: a promising system for drug delivery. Naresuan Univ J. 2013;11:51–66.
Chen M-C, Mi F-L, Liao Z-X, Hsiao C-W, Sonaje K, Chung M-F, Hsu LW, Sung HW. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev. 2013;65:865–79.
Liu L, Yao W, Rao Y, Lu X, Gao J. pH-responsive carriers for oral drug delivery: challenges and opportunities of current platforms. Drug Delivery. 2017;24:569–81.
Gao P, Xia G, Bao Z, Feng C, Cheng X, Kong M, Liu Y, Chen X. Chitosan based nanoparticles as protein carriers for efficient oral antigen delivery. Int J Biol Macromol. 2016;91:716–23.
Yao X, Bunt C, Cornish J, Quek S-Y, Wen J. Oral delivery of lactoferrin: a review. Int J Pept Res Ther. 2013;19:125–34.